Immunomodulatory molecules are critical in enhancing the immune system's ability to recognize and attack cancer cells. These include immune checkpoint inhibitors, cytokines, and monoclonal antibodies that modulate immune responses. By targeting pathways like PD-1/PD-L1 and CTLA-4, they overcome tumor-induced immune suppression. At the Cancer Research and Development Conference 2025, experts will explore how these therapies revolutionize cancer treatment by boosting immune responses, offering hope for improved outcomes in various malignancies. Advances in this field are driving innovative cancer treatments, providing new avenues for patients and clinicians alike.